The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

However, several key assets, including TEVA's movement disorder therapy Austedo, its new schizophrenia drug Uzedy, and the company's generic portfolio, offset the impact. Revenue from Austedo ...

The company credited much of that growth to higher generic sales around the world plus the continued strength of branded drugs Austedo, Uzedy and Ajovy. As for 2025, Teva expects to generate sales ...

In the fourth quarter, U.S. sales of Ajovy rose 11% to $63 million, while Austedo grew 27% to $518 million, and Uzedy sales soared to $43 million from $9 million a year earlier.

The decline was partially offset by higher revenues from generic products globally and strong growth from branded drugs, Austedo, Ajovy and Uzedy, along with the sale of certain product rights.

Recent notable product launches include Ajovy (migraine treatment), Austedo (treatment for tardive dyskinesia and chorea associated with Huntington’s disease), and Uzedy (schizophrenia treatment).

AUSTEDO Revenue: $1.7 billion, up 36%. AJOVY Revenue: Over $0.5 billion, up 18%. UZEDY Revenue: $117 million. Generics Business Revenue: Close to $9.5 billion, up 11%. API Business Growth ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...